Remove 2015 Remove Clinical Trials Remove Safety
article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

The joint study conducted by Ben Gurion University and Soroka Medical Center in Beersheba analyzed 188 teens diagnosed with Autistic Spectrum Disorder (ASD) between 2015 and 2017. Unfortunately, the conventional pharmaceuticals used to treat these symptoms have significant side effects leaving families with no solution. References Staff, T.

article thumbnail

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma – ResearchAndMarkets.com

Cannabis Law Report

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Global Skin Cancer Drugs Historic Market, 2015-2020, $ Billion. Skin Cancer Drugs Market Size And Growth. Actinic Keratoses (AK).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

Therapy 104
article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

article thumbnail

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

We will be joined by excellent speakers including Dr. Thomas Insel – Former Director of the US National Institute of Mental Health (2002 – 2015), Prof. The partnership will be officially launched at the virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies taking place on 23rd June, 14:00 – 16:00 CEST. David Nutt and Prof.

Access 52
article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 45